Literature DB >> 19651157

Clusterin: a forgotten player in Alzheimer's disease.

Tapio Nuutinen1, Tiina Suuronen, Anu Kauppinen, Antero Salminen.   

Abstract

Clusterin, also known as apolipoprotein J, is a versatile chaperone molecule which contains several amphipathic and coiled-coil alpha-helices, typical characteristics of small heat shock proteins. In addition, clusterin has three large intrinsic disordered regions, so-called molten globule domains, which can stabilize stressed protein structures. Twenty years ago, it was demonstrated that the expression of clusterin was clearly increased in Alzheimer's disease (AD). Later it was observed that clusterin can bind amyloid-beta peptides and prevent their fibrillization. Clusterin is also involved in the clearance of amyloid-beta peptides and fibrils by binding to megalin receptors and enhancing their endocytosis within glial cells. Clusterin is a complement inhibitor and can suppress complement activation observed in AD. Clusterin is also present in lipoprotein particles and regulates cholesterol and lipid metabolism of brain which is disturbed in AD. Clusterin is a stress-induced chaperone which is normally secreted but in conditions of cellular stress, it can be transported to cytoplasm where it can bind to Bax protein and inhibit neuronal apoptosis. Clusterin can also bind to Smad2/3 proteins and potentiate the neuroprotective TGFbeta signaling. An alternative splicing can produce a variant isoform of clusterin which can be translocated to nuclei where it induces apoptosis. The role of nuclear clusterin in AD needs to be elucidated. We will review here the extensive literature linking clusterin to AD and examine the recent progress in clusterin research with the respect to AD pathology. Though clusterin can be viewed as a multipotent guardian of brain, it is unable to prevent the progressive neuropathology in chronic AD.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19651157     DOI: 10.1016/j.brainresrev.2009.05.007

Source DB:  PubMed          Journal:  Brain Res Rev        ISSN: 0165-0173


  109 in total

1.  Novel late-onset Alzheimer disease loci variants associate with brain gene expression.

Authors:  Mariet Allen; Fanggeng Zou; High Seng Chai; Curtis S Younkin; Julia Crook; V Shane Pankratz; Minerva M Carrasquillo; Christopher N Rowley; Asha A Nair; Sumit Middha; Sooraj Maharjan; Thuy Nguyen; Li Ma; Kimberly G Malphrus; Ryan Palusak; Sarah Lincoln; Gina Bisceglio; Constantin Georgescu; Debra Schultz; Fariborz Rakhshan; Christopher P Kolbert; Jin Jen; Jonathan L Haines; Richard Mayeux; Margaret A Pericak-Vance; Lindsay A Farrer; Gerard D Schellenberg; Ronald C Petersen; Neill R Graff-Radford; Dennis W Dickson; Steven G Younkin; Nilüfer Ertekin-Taner; Liana G Apostolova; Steven E Arnold; Clinton T Baldwin; Robert Barber; Michael M Barmada; Thomas Beach; Gary W Beecham; Duane Beekly; David A Bennett; Eileen H Bigio; Thomas D Bird; Deborah Blacker; Bradley F Boeve; James D Bowen; Adam Boxer; James R Burke; Jacqueline Buros; Joseph D Buxbaum; Nigel J Cairns; Laura B Cantwell; Chuanhai Cao; Chris S Carlson; Regina M Carney; Steven L Carroll; Helena C Chui; David G Clark; Jason Corneveaux; Carl W Cotman; Paul K Crane; Carlos Cruchaga; Jeffrey L Cummings; Philip L De Jager; Charles DeCarli; Steven T DeKosky; F Yesim Demirci; Ramon Diaz-Arrastia; Malcolm Dick; Beth A Dombroski; Ranjan Duara; William D Ellis; Denis Evans; Kelley M Faber; Kenneth B Fallon; Martin R Farlow; Steven Ferris; Tatiana M Foroud; Matthew Frosch; Douglas R Galasko; Paul J Gallins; Mary Ganguli; Marla Gearing; Daniel H Geschwind; Bernardino Ghetti; John R Gilbert; Sid Gilman; Bruno Giordani; Jonathan D Glass; Alison M Goate; Robert C Green; John H Growdon; Hakon Hakonarson; Ronald L Hamilton; John Hardy; Lindy E Harrell; Elizabeth Head; Lawrence S Honig; Matthew J Huentelman; Christine M Hulette; Bradley T Hyman; Gail P Jarvik; Gregory A Jicha; Lee-Way Jin; Gyungah Jun; M Ilyas Kamboh; Jason Karlawish; Anna Karydas; John S K Kauwe; Jeffrey A Kaye; Nancy Kennedy; Ronald Kim; Edward H Koo; Neil W Kowall; Patricia Kramer; Walter A Kukull; James J Lah; Eric B Larson; Allan I Levey; Andrew P Lieberman; Oscar L Lopez; Kathryn L Lunetta; Wendy J Mack; Daniel C Marson; Eden R Martin; Frank Martiniuk; Deborah C Mash; Eliezer Masliah; Wayne C McCormick; Susan M McCurry; Andrew N McDavid; Ann C McKee; Marsel Mesulam; Bruce L Miller; Carol A Miller; Joshua W Miller; Thomas J Montine; John C Morris; Amanda J Myers; Adam C Naj; Petra Nowotny; Joseph E Parisi; Daniel P Perl; Elaine Peskind; Wayne W Poon; Huntington Potter; Joseph F Quinn; Ashok Raj; Ruchita A Rajbhandary; Murray Raskind; Eric M Reiman; Barry Reisberg; Christiane Reitz; John M Ringman; Erik D Roberson; Ekaterina Rogaeva; Roger N Rosenberg; Mary Sano; Andrew J Saykin; Julie A Schneider; Lon S Schneider; William Seeley; Michael L Shelanski; Michael A Slifer; Charles D Smith; Joshua A Sonnen; Salvatore Spina; Peter St George-Hyslop; Robert A Stern; Rudolph E Tanzi; John Q Trojanowski; Juan C Troncoso; Debby W Tsuang; Vivianna M Van Deerlin; Badri Narayan Vardarajan; Harry V Vinters; Jean Paul Vonsattel; Li-San Wang; Sandra Weintraub; Kathleen A Welsh-Bohmer; Jennifer Williamson; Randall L Woltjer
Journal:  Neurology       Date:  2012-06-20       Impact factor: 9.910

2.  Withania somnifera reverses Alzheimer's disease pathology by enhancing low-density lipoprotein receptor-related protein in liver.

Authors:  Neha Sehgal; Alok Gupta; Rupanagudi Khader Valli; Shanker Datt Joshi; Jessica T Mills; Edith Hamel; Pankaj Khanna; Subhash Chand Jain; Suman S Thakur; Vijayalakshmi Ravindranath
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-30       Impact factor: 11.205

3.  The chaperone protein clusterin may serve as a cerebrospinal fluid biomarker for chronic spinal cord disorders in the dog.

Authors:  Intan N F Shafie; Mark McLaughlin; Richard Burchmore; Mary Ann A Lim; Paul Montague; Pamela E J Johnston; Jacques Penderis; Thomas J Anderson
Journal:  Cell Stress Chaperones       Date:  2013-08-29       Impact factor: 3.667

Review 4.  The role of clusterin in Alzheimer's disease: pathways, pathogenesis, and therapy.

Authors:  Jin-Tai Yu; Lan Tan
Journal:  Mol Neurobiol       Date:  2012-01-25       Impact factor: 5.590

Review 5.  Dysregulation of Rab5-mediated endocytic pathways in Alzheimer's disease.

Authors:  Wei Xu; Fang Fang; Jianqing Ding; Chengbiao Wu
Journal:  Traffic       Date:  2018-02-05       Impact factor: 6.215

6.  Osteopontin and clusterin levels in type 2 diabetes mellitus: differential association with peripheral autonomic nerve function.

Authors:  Raelene E Maser; M James Lenhard; Ryan T Pohlig; P Babu Balagopal
Journal:  Neurol Sci       Date:  2017-06-21       Impact factor: 3.307

Review 7.  The genetics and neuropathology of Alzheimer's disease.

Authors:  Gerard D Schellenberg; Thomas J Montine
Journal:  Acta Neuropathol       Date:  2012-05-23       Impact factor: 17.088

Review 8.  Alzheimer disease: epidemiology, diagnostic criteria, risk factors and biomarkers.

Authors:  Christiane Reitz; Richard Mayeux
Journal:  Biochem Pharmacol       Date:  2014-01-04       Impact factor: 5.858

Review 9.  Proteomic approaches and identification of novel therapeutic targets for alcoholism.

Authors:  Giorgio Gorini; R Adron Harris; R Dayne Mayfield
Journal:  Neuropsychopharmacology       Date:  2013-07-31       Impact factor: 7.853

10.  Combined effects of Alzheimer risk variants in the CLU and ApoE genes on ventricular expansion patterns in the elderly.

Authors:  Florence F Roussotte; Boris A Gutman; Sarah K Madsen; John B Colby; Paul M Thompson
Journal:  J Neurosci       Date:  2014-05-07       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.